摘要
目的:探讨Graves病(GD)患者血清Th1/Th2趋化因子CXCL10和CCL22水平的变化及其临床意义。方法:76例GD患者按照诊治阶段分为治疗前组34例、治疗缓解组22例和治疗平稳组20例,选择同期健康查体者15例作为对照组。抽取各组清晨空腹肘正中静脉血,测定甲状腺功能和甲状腺抗体水平,酶联免疫吸附测定(ELISA)法检测血清趋化因子CXCL10和CCL22的水平,并结合患者临床指标进行分析。结果:GD患者血清CXCL10、CCL22水平及CXCL10/CCL22在治疗前组明显高于治疗后各组及对照组(P<0.05或P<0.001)。治疗后患者血清CXCL10和CCL22水平明显下降,治疗缓解组甚至低于对照组(均P<0.01)。GD患者治疗前血清CXCL10和CCL22均与患者血清游离甲状腺素(FT4)水平呈正相关(rs分别为0.538和0.389,P<0.05)。结论:趋化因子CXCL10和CCL22参与GD的免疫调控,并且与疾病进程有关,可为免疫学监测提供新的思路。
Objective： To explore the changes and clinical significance of serum
Th1/Th2 chemokines CXCL10 and CCL22 in patients with Graves disease. Methods：
Seventy-six patients with Graves disease were divided into untreated group （n=34）,
remission group （n=22） and stable group （n=20） according to the different stages
of treatment. Fifteen healthy subjects were selected for the control. The levels
of thyroid function and thyroid antibody were detected using fasting blood. The
serum levels of CXCL10 and CCL22 were detected by enzyme-linked immunosorbent
assay （ELISA）. Results： The serum levels of CXCL10 and CCL22, and the ratio of
CXCL10/CCL22 were significantly increased in untreated group than those after
treatment as control group（P 〈 0.05 or P 〈 0.01）. The serum levels of CXCL10 and
CCL22 were significantly decreased after treatment （P 〈 0.01）, and the levels were
lower in remission group than those of control （P 〈 0.01）. The levels of CXCL10
and CCL22 were positively correlated with FT4 （r = 0.538,r = 0.389, respectively,
P 〈 0.05）. Conclusion： Th1/Th2 chemokines CXCL10 and CCL22 were involved in the
immune regulation of Graves disease and may become new means to explore the inner
links and process of the disease.
出处
《天津医药》
CAS
北大核心
2011年第6期502-504,共3页
Tianjin Medical Journal
